BOSULIF vs EVEROLIMUS

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 19, 2026·How we rate

Possible drug interaction. BOSULIF and EVEROLIMUS are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BOSULIF	EVEROLIMUS
Rating	New	70/100
Pharmacy pays	—	~$229.16 /30
Type	RX	RX
Active ingredient	BOSUTINIB MONOHYDRATE	EVEROLIMUS
Manufacturer	Pf Prism Cv	Biocon Pharma
Dosage forms	Capsule, Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Half-life	—	about 30 hours (mean terminal elimination half-life)
Treats	Bcr-Abl Positive Chronic Myelogenous Leukemia	—

bosulif everolimus

Rating

New

70/100

Pharmacy pays

—

~$229.16 /30

Type

Active ingredient

BOSUTINIB MONOHYDRATE

EVEROLIMUS

Manufacturer

Pf Prism Cv

Biocon Pharma

Dosage forms

Capsule, Tablet

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Half-life

—

about 30 hours (mean terminal elimination half-life)

Treats

Bcr-Abl Positive Chronic Myelogenous Leukemia

—

Frequently asked questions

What is the difference between Bosulif and Everolimus?

Bosulif contains Bosutinib Monohydrate, while Everolimus contains Everolimus — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.